Microbix Biosystems (MBX) Q2 2025 earnings summary

Executive summary

• Q2 revenue reached CAD 5.3 million (down 5% year-over-year), with strong antigen sales and slower QAPs sales due to one-off factors and customer delays.

• Gross margin improved to 60% in Q2, up 7% year-over-year, and net earnings for the first half were CAD 900,000.

• Operational upgrades, including new recombinant capabilities and automation, are expanding addressable markets and improving efficiency.

• Strategic progress continues with new customer onboardings and leadership in molecular diagnostics and emerging pathogens.

• Liquidity improved despite debt repayment and share repurchases.

Financial highlights

• First half total revenue was CAD 11.4 million, with gross margins up 10% year-over-year to 61%.

• Q2 net income was $20,664, down from $377,730 in Q2 2024; H1 net income was $877,627, down from $2,833,109 due to prior year licensing fees.

• Cash and equivalents at March 31, 2025, were $14.5 million, up $1.5 million sequentially after $1.2 million debt repayment and $0.7 million share repurchases.

• Credit line doubled from CAD 2 million to CAD 4 million.

• Cash provided by operating activities in H1 was $1,759,454, compared to $2,178,196 in H1 2024.

Outlook and guidance

• Second half expected to be more challenging, with weaker test ingredient sales, especially in China, partially offset by strength in antigens.

• QAPs segment expected to rebound in the back half of the year, with new customer onboarding providing strategic visibility.

• Ample liquidity to withstand tactical revenue headwinds and continue strategic execution.